We aim to become the global biotech company
based on proprietary technology.
R&D based company with mass cell culture technology and cell quality management technology
Patented in countries
leading new drug development market
Enter the global biotech market
with Proprietary technology
Intellectual Property
Cell2in is committed to protect our core technology by establishment of intellectual property in the field of cell therapy
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| Real-time Imaging Sensor for Measuring Cellular Thiol Levels | Korea | 10-1862581 | 2018. 05. 24 |
| United States | 10.215.757B2 | 2019. 02. 26 | |
| Korea | 10-1983803 | 2019. 05. 23 | |
| United States | 10.620.215 | 2020. 04. 14 | |
| Real-time Fluorescence Imaging Sensor for Estimating the Glutathione in Cellular Organelle and Manufacturing Method Thereof | Korea | 10-2133794 | 2020. 07. 08 |
| Canada (application) | 3.072.434 | 2020. 02. 07 | |
| Australia (application) | 2018320601 | 2020. 02. 19 | |
| United States (application) | 16/640717 | 2020. 02. 20 | |
| Europe (application) | 18848372.1 | 2020. 02. 21 | |
| China (application) | 201880054675.0 | 2020. 02. 21 | |
| India (application) | 202017007994 | 2020. 02. 25 | |
| Japan (application) | 2020-511502 | 2020. 02. 19 | |
| Real-time Fluorescence Imaging Sensor for Estimating the Glutathione in Endoplasmic Reticulum and a Method of Using It | Korea | 10-2019-0178260 | 2019. 12. 30 |
Gene Biomarker
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| FreSHtracer-based Application of the Genetic Profile of Separated Cells | PCT | PCT/KR 2018/008239 | 2018. 07. 20 |
Stem Cell Therapy
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| Composite for Treatment of Thrombocytopenia | Korea | 10-2021-0063975 | 2021. 05. 18 |
| Gene Market for Evaluating the Characteristics of Stem Cells and the Use of the Same | Korea | 10-2020-0180455 | 2020. 12. 22 |
Cell Quality Control
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| Method of Therapeutic Cell Quality Improvement Based on Real-time Glutathione Measurement | Korea | 10-2119714 | 2020. 06. 01 |
| Europe (application) | 18883520.1 | 2020. 05. 27 | |
| China (application) | 201880077266.2 | 2020. 05. 28 | |
| Japan (application) | 2020-546264 | 2020. 05. 27 | |
| United States (application) | 16/767985 | 2020. 05. 28 | |
| Method of Therapeutic Cell Quality Measurement Based on Real-time Glutathione Measurement | Korea | 10-2145929 | 2020. 08. 12 |
| United States (application) | 16/768014 | 2020. 05. 28 | |
| Europe (application) | 18884812.1 | 2020. 05. 27 | |
| China (application) | 201880077236.1 | 2020. 05. 28 | |
| Japan (application) | 2020-546265 | 2020. 05. 27 |
Publication
Cell2in has continuously published its research results through famous academic societies and journals.
Development Technology and Pluripotent Stem Cells : K. Kim et al., Improved Isolation and Culture of Urine-Derived Stem Cells (USCs) and Enhanced Production of Immune Cells from the USC-Derived Induced Pluripotent Stem Cells, J. Clin. Med. (2020), 9, 827
The availability of autologous adult stem cells is one of the essential prerequisites for
human stem cell therapy. Urine-derived stem cells (USCs) are considered as desirable cell sources for
cell therapy because donor-specific USCs are easily and non-invasively obtained from urine. Efficient
isolation, expansion, and differentiation methods of USCs are necessary to increase their availability.
Here, we developed a method for efficient isolation and expansion of USCs using Matrigel, and the
rho-associated protein kinase (ROCK) inhibitor, Y-27632. The prepared USCs showed significantly
enhanced migration, colony forming capacity, and differentiation into osteogenic or chondrogenic
lineage. The USCs were successfully reprogramed into induced pluripotent stem cells (USC-iPSCs)
and further differentiated into kidney organoid and hematopoietic progenitor cells (HPCs). Using
flavonoid molecules, the isolation efficiency of USCs and the production of HPCs from the USC-iPSCs
was increased. Taken together, we present an improved isolation method of USCs utilizing Matrigel,
a ROCK inhibitor and flavonoids, and enhanced differentiation of USC-iPSC to HPC by flavonoids.
These novel findings could significantly enhance the use of USCs and USC-iPSCs for stem cell research
and further application in regenerative stem cell-based therapies.
human stem cell therapy. Urine-derived stem cells (USCs) are considered as desirable cell sources for
cell therapy because donor-specific USCs are easily and non-invasively obtained from urine. Efficient
isolation, expansion, and differentiation methods of USCs are necessary to increase their availability.
Here, we developed a method for efficient isolation and expansion of USCs using Matrigel, and the
rho-associated protein kinase (ROCK) inhibitor, Y-27632. The prepared USCs showed significantly
enhanced migration, colony forming capacity, and differentiation into osteogenic or chondrogenic
lineage. The USCs were successfully reprogramed into induced pluripotent stem cells (USC-iPSCs)
and further differentiated into kidney organoid and hematopoietic progenitor cells (HPCs). Using
flavonoid molecules, the isolation efficiency of USCs and the production of HPCs from the USC-iPSCs
was increased. Taken together, we present an improved isolation method of USCs utilizing Matrigel,
a ROCK inhibitor and flavonoids, and enhanced differentiation of USC-iPSC to HPC by flavonoids.
These novel findings could significantly enhance the use of USCs and USC-iPSCs for stem cell research
and further application in regenerative stem cell-based therapies.